ETON

$ETON chatter on StockTwits

• 
  Northridge G-101 SPM Company@G101SPM23m

  $ETON $50.08 ask DAC (dollar average cost including partial SELLS at profit to reduce cost to zero) $00.00 https://stocktwits.com/G101SPM/message/654597956 BRIEF: Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025 Q2 2026 fully diluted GAAP EPS of $0.35, non-GAAP fully diluted EPS of $0.43; EBITDA of $14.1 million, Adjusted EBITDA of $16.2 million Raising full year revenue guidance, with 2026 revenue now expected to exceed $145 million, up from previous guidance of more than $120 million Relaunched HEMANGEOL® May 1st, patient conversion completed ahead of schedule Acquired late-stage product candidate ASN-001, expanding the Company’s infantile hemangioma franchise, and providing a potential high-value 2027 NDA submission Submitted Prior Approval Supplement to the FDA to expand indication of KHINDIVI®, allowing for potential H1 2027 approval of expanded indication Received FDA Fast Track designation for endocrinology development product AMGLIDIA® Acquired U.S. commercialization rights to orphan drug IMPAVIDO®

  View on StockTwits ↗
• 
  Bill Blanke@herousa8h

  $ETON Legendary call here Jack.

  View on StockTwits ↗
• 
  Maverik@MaverikIT8h

  $ETON

  View on StockTwits ↗
• 
  Maverik@MaverikIT8h

  $ETON nice ER pop$

  View on StockTwits ↗
• 
  Top Stock Alerts@topstockalerts9h

  After Hours Top Gainers PT2 $MDXH $DARE $HTFL $ETON $TPCS

  View on StockTwits ↗
• 
  Paperstocks89@Paperstocks89Bullish9h

  $ETON print 54-56!

  View on StockTwits ↗
• 
  DonCorleone77@DonCorleone7710h

  $ETON $HTFL $NU $AEYE $RDDT AFTER-HOURS MOVERS: Currently Higher After Earnings: - Eton Pharmaceuticals (ETON) up 21.3% - Heartflow. (HTFL) up 24.3% - Nu Holdings (NU) up 8.4% - AudioEye, Inc. (AEYE) up 4.7% Currently Also Higher: - Reddit (RDDT) up 12.4% on S&P 500 inclusion Currently Lower After Earnings: - Intellicheck, Inc. (IDN) down 17.9% - ARS Pharmaceuticals (SPRY) down 13.5% - Globant S.A. (GLOB) down 13.4% - Applied Materials (AMAT) down 5.0% - HawkEye 360 (HAWK) down 1.3%

  View on StockTwits ↗
• 
  Top Stock Alerts@topstockalerts10h

  Eton Pharmaceuticals shares surged in after-hours trading after the company delivered an exceptional second-quarter 2026 report. Revenue nearly doubled year over year to $37.6 million, far exceeding the $26.88 million analyst consensus, while adjusted EPS of $0.43 was almost three times the $0.15 expected. Management also significantly raised its 2026 revenue outlook to more than $145 million, up from its previous forecast of over $120 million, signaling strong commercial momentum across its rare-disease portfolio. Profitability improved sharply as adjusted EBITDA jumped to $16.2 million from $3.1 million a year earlier, lifting the adjusted EBITDA margin to 43% from 16%. The strong results were complemented by H.C. Wainwright raising its price target to $65 from $57 while maintaining a Buy rating. $ETON

  View on StockTwits ↗
• 
  Aura@ExploringTradesBullish10h

  Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $TPCS $ONEG $ETON $MGRX news $

  View on StockTwits ↗
• 
  Adam@Adamchristlover10h

  $ETON Legend I made tons of money because of your calls worth every penny to join you.

  View on StockTwits ↗
• 
  Paperstocks89@Paperstocks89Bullish11h

  $ETON as usual the bitches selling let this thing rip finally haters

  View on StockTwits ↗
• 
  Top Stock Alerts@topstockalerts11h

  $ETON the market is giving this stock every chance to continue.

  View on StockTwits ↗
• 
  Paperstocks89@Paperstocks8912h

  $ETON why is this not printing 54

  View on StockTwits ↗
• 
  Dustin@bryantboy9912h

  $ETON Bahahahahahahah

  View on StockTwits ↗
• 
  Munger Charliee@CharlieeMungerTWITS12h

  $CELC Peeps forget that FDA approval isn’t always the finish line for a biotech stock. Sometimes it’s the beginning of the rerating. Look at $ETON. The stock initially struggled around approval, then climbed dramatically as the market started pricing in commercialization and revenue rather than simply the binary FDA event. That’s why today’s CELC call matters. No surprise delay, commercialization infrastructure is ready, launch remains on track and the balance sheet gives them SUBSTANTIAL runway. Now the story shifts from “Will the FDA approve it?” to “How big can this launch become?” CELC doesn’t need to be profitable tomorrow to move substantially higher. If early uptake starts validating the commercial opportunity, Wall Street will price that growth well before the profits actually arrive. ETON already gave biotech investors a pretty good lesson in how that works. $120-$150 doesn’t require magic. It requires execution. Today was another step in that direction.

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.